Damien Vansteene

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

J. Guigay, Jérôme Fayette, Cédrik Lafond et al. · Journal of Clinical Oncology · 2019 · 82 citations

Medicine, Oncology, Pharmacology +14

NutriCancer: A French observational multicentre cross-sectional study of malnutrition in elderly patients with cancer

Jean Lacau St Guily, Éric Bouvard, Bruno Raynard et al. · Journal of Geriatric Oncology · 2017 · 62 citations

Agriculture, Nutritional Sciences, Oncology +14

Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial

J. Guigay, Manish R. Patel, Amaury Daste et al. · Journal for ImmunoTherapy of Cancer · 2021 · 27 citations · Full text

Medicine, Oncology, Pharmacology +17

TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

J. Guigay, Jérôme Fayette, Esma Saâda-Bouzid et al. · Journal of Clinical Oncology · 2020 · 26 citations

Medicine, Oncology, Chemotherapy +10